Ablynx NV (XBRU:ABLXS) 3-Year Revenue Growth Rate : -1.50% (As of Dec. 2017)

View and export this data going back to . Start your Free Trial

What is Ablynx NV 3-Year Revenue Growth Rate?

Ablynx NV's Revenue per Share for the six months ended in Dec. 2017 was €0.49.

During the past 12 months, Ablynx NV's average Revenue per Share Growth Rate was -30.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was -1.50% per year. During the past 5 years, the average Revenue per Share Growth Rate was 13.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 10.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 12 years, the highest 3-Year average Revenue per Share Growth Rate of Ablynx NV was 52.50% per year. The lowest was -10.00% per year. And the median was 22.70% per year.

Competitive Comparison of Ablynx NV's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Ablynx NV's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ablynx NV's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Ablynx NV's 3-Year Revenue Growth Rate falls into.

Ablynx NV 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Ablynx NV (XBRU:ABLXS) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Ablynx NV 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Ablynx NV's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines